Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21483
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 301–312 of 21,483 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
79
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Active, not recruiting Phase 3 Interventional

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
72
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Recruiting Not applicable Interventional

FIBERGRAFT Aeridyan Posterolateral Fusion Study

NCT07059065
View directory record Official record
Conditions
Degenerative Spine Disease
Interventions
FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute, Demineralized Bone Matrix
Device
Lead sponsor
DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
429
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Active, not recruiting Phase 3 Interventional

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)
Drug · Radiation
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
60
States / cities
Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Recruiting No phase listed Observational

A Longitudinal Natural History Study of Immune Biomarkers in Neuropsychiatric Illness

NCT07877246
View directory record Official record
Conditions
Neuropsychiatric Disorders, Neuroinflammatory Disorders, Post-Infectious Neuropsychiatric Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
1 Month to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

NCT06690398
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Lumateperone high dose, Lumateperone low dose, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
35
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Trial of Pistachio Consumption in Older Adults

NCT06992544
View directory record Official record
Conditions
Cognition, Cardiometabolic Risk Factors, Life Satisfaction
Interventions
Pistachio-enriched diet, Usual diet
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Recruiting Phase 4 Interventional

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Active, not recruiting Not applicable Interventional

INHANCE Stemless Reverse Shoulder IDE

NCT06323980
View directory record Official record
Conditions
Arthroplasty, Replacement, Shoulder
Interventions
Reverse Total Shoulder
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST
Completed No phase listed Observational Results available

Philips Intracardiac Echocardiography (ICE) Clinical Registry

NCT04950192
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions
ICE Image guidance
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 7, 2026, 2:45 PM EST